Readout Capital
Overview
Readout Capital is a biotechnology-focused investment firm that employs a long/short equity strategy, conducting fundamental research to invest in both public and private life sciences companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Epicrispr Biotechnologies | Aug 2026 | Series C | Co-investor |
| Nava Therapeutics | - | Seed | Co-investor |
Key People
James Dahlman
Chief Scientific Officer
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Readout Capital based?
Readout Capital is headquartered in Washington D.C., United States.
When was Readout Capital founded?
Readout Capital was founded in 2023.
How many portfolio companies does Readout Capital have?
Readout Capital has 2 portfolio companies in Caplight's dataset.
What are some companies in Readout Capital's portfolio?
Portfolio companies visible on Caplight include Epicrispr Biotechnologies, Nava Therapeutics.
What was Readout Capital's most recent investment shown here?
Readout Capital's most recent investment in this portfolio sample was in Epicrispr Biotechnologies in 2026.
What sectors does Readout Capital focus on?
Readout Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Readout Capital focus on?
Readout Capital typically invests at the Early stage.
What is Readout Capital's AUM?
Readout Capital's assets under management are estimated between $25.9M and $25.9M.